TABLE 5.
Effective dose predictions for a panel of biotherapeutics.
| Drug | Model predicted dose | Clinically approved dose | ||
|---|---|---|---|---|
| Model in Applied BioMath Assess ™ | ID90/TE98 (mg) a | Dose (mg) | Schedule a | |
| Remicade (infliximab) | Monospecific anti-ligand | 441 | 210 | 8 weeks IV |
| Humira (adalimumab) | Monospecific anti-ligand | 39.4 | 40 | 2 weeks SC |
| Stelara (ustekinumab) | Monospecific anti-ligand | 22.4 | 45 | 12 weeks SC |
| Skyrizi (risankizumab) | Monospecific anti-ligand | 273 | 150 | 12 weeks SC |
| 37.1 | 150 | 4 weeks SC | ||
| Benlysta (belimumab) | Monospecific anti-ligand | 252 | 200 | 1 week SC |
| 1700 | 700 | 4 weeks IV | ||
| Xolair (omalizumab) | Monospecific anti-ligand | 330 | 225 | 2 weeks SC |
| Herceptin (trastuzumab) | Monospecific anti-receptor (4 compartment) | 79.0 | 140 | 1 week IV |
| Vectibix (panitumumab) | Monospecific anti-receptor (4 compartment) | 162 | 420 | 2 weeks IV |
| Rybrevant (amivantamab) | Bispecific anti-receptor x anti-receptor (4 compartment) | 740 | 1050 | 2 weeks IV |
a
ID90 = dose to achieve 90% inhibition, TE98 = dose to achieve 98% target engagement, SC = subcutaneous administration, IV = intravenous administration.